Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Partially Offset by Impact From Stelara, Simponi/Simponi Aria, Remicade, Opsumit/Opsynvi and Imbruvica >JNJ

Dow Jones2026/10/13 10:20

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Brent Crude Fell 12.5% But Former Biden Advisor Warns Iran War Could Return

BeInCrypto•2026/11/09 02:39

Cathie Wood Blames Anthropic’s CEO for AI Panic: Why Attack a Company Her Fund Backs?

BeInCrypto•2026/11/08 22:24

Anthropic's $1.5 Trillion IPO: What Investors Should Know Before Buying

BeInCrypto•2026/11/08 14:42

Why is the US Dollar Falling? Midterms, Yields, and a Critical Economic Test

BeInCrypto•2026/11/08 02:42